Biochem/physiol Actions
MLR-1023 has a therapeutic potential to treat type 2 diabetes.
MLR-1023 is a potent, orally active, allosteric activator of the non-receptor Src-related Lyn kinase that produces lasting glucose lowering, reduces HbA1c levels, and preserves pancreatic β-cells in db/db mice. MLR-1023 increased insulin receptor sensitivity. MLR-1023 (Tolimidone) is antiulcer agent.
MLR-1023 is a potent, orally active, allosteric activator of the non-receptor Src-related Lyn kinase; insulin receptor-potentiating agent; antiulcer agent.
Features and Benefits
This compound is a featured product for Kinase Phosphatase Biology research. Click here to discover more featured Kinase Phosphatase Biology products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the InsR page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
| Quality Segment | 100 |
| assay | ≥98% (HPLC) |
| form | powder |
| color | white to beige |
| solubility | DMSO: 15 mg/mL (clear solution) |
| storage temp. | room temp |
| SMILES string | Cc1cccc(OC2=CNC(=O)N=C2)c1 |
| InChI | 1S/C11H10N2O2/c1-8-3-2-4-9(5-8)15-10-6-12-11(14)13-7-10/h2-7H,1H3,(H,12,13,14) |
| InChI key | HJQILFPVRNHTIG-UHFFFAOYSA-N |
